| Literature DB >> 34751114 |
Anju Kumari1, Rimpy Kaur Chowhan1, Pushpa Kakchingtabam2, Sharifun Shahnaj2, Hamidur Rahaman2, Mohd Saquib Ansari3, Laishram Rajendrakumar Singh1.
Abstract
The moonlighting protein, Prdx-6, exhibits peroxidase activity, phospholipase activity, and lysophosphatidylcholine acyltransferase (LPCAT) activity. Although it is ubiquitous in expression, its level is prominently high in the lung. Prdx-6 has been known to be an important enzyme for the maintenance of normal lung physiologies including, anti-oxidant defense, lung surfactant homeostasis, and cell signaling. Studies further unveiled that the altered activity (peroxidase or ai- PLA2) of this enzyme is linked with various lung pathologies or diseases. In the present article, we attempted to address the various pathophysiologies or disease conditions (like lung ischemia, hyperoxia, lung cancer, emphysema, and acute lung injury) wherein Prdx-6 is involved. The study implicates that Prdx-6 could be used as a common drug target for multiple lung diseases. Important future insights have also been incorporated. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Peroxiredoxin-6 ; acute lung injury ; antioxidants ; hyperoxia ; pulmonary microvascular endothelial cells (PMVEC) .; reactive oxygen species (ROS)
Mesh:
Substances:
Year: 2021 PMID: 34751114 DOI: 10.2174/1389203722666211109101853
Source DB: PubMed Journal: Curr Protein Pept Sci ISSN: 1389-2037 Impact factor: 3.272